In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Boston Scientific shells out $500mm up front for Augmenix

Executive Summary

In its seventh acquisition this year, Boston Scientific Corp. is paying $500mm in cash to acquire closely held device maker Augmenix Inc. The transaction also includes up to $100mm in sales-based earn-outs.
Deal Industry
  • Biotechnology
  • Medical Devices
    • Biomaterials
    • Implantable Devices
Deal Status
  • Final
Deal Type
  • Acquisition
    • Payment Includes Cash
    • Acquisition of Private Biotech
    • Includes Earnout
    • Full Acquisition

Related Companies

Advertisement
UsernamePublicRestriction

Register